Compare Repligen Corporation Common Stock (RGEN) vs SanDisk (SNDK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs SanDisk — how do they compare? Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B), while SanDisk trades at $1,342.99 (market cap $202.82B). The key difference: SanDisk is far larger — about 17.9× Repligen Corporation Common Stock's market cap, and SanDisk is more actively traded (7,345,106 versus 1,216,919). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and SanDisk for 10 Days on average.
| RGEN | SNDK | |
|---|---|---|
Market Cap | $11.31B | $202.82B |
Volume | 1,216,919 | 7,345,106 |
Sector | Health | Technology |
52-Week High | $194.57 | $2.34K |
52-Week Low | $102.87 | $140.16 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $11.20B | $198.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SNDK trades at $1,482.33, down 0.34% amid sector-wide pressure from Chinese competition concerns. The stock shows bearish technical signals with strong analyst support (87.5% buy rating) and a $2,160 consensus price target. Recent earnings beats contrast with current negative profitability, though 2026 projections show dramatic improvement to $11.4B net income. The company maintains strong balance sheet fundamentals with $1.48B cash and manageable debt levels.
SNDK presents a compelling risk-reward opportunity with significant upside potential to analyst targets, though near-term volatility from memory sector headwinds persists. The company's AI memory positioning and projected 2026 profitability growth support long-term bullish thesis, while current technical weakness may offer attractive entry points for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About SanDisk
Sandisk is a semiconductor memory company specializing in NAND flash technology. Its storage products support consumer devices, enterprise systems, and cloud and AI infrastructure.
Read more on SNDK →
